Cartesian Therapeutics (RNAC) Tops Q2 EPS by 50c

Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 EPS of $0.50. Revenue for the quarter came in at $300 thousand.

For earnings history and earnings-related data on Cartesian Therapeutics (RNAC) click here.

You May Also Be Interested In

• Crude Inventory Rose 3 Million Barrels Last Week - EIA
• Active options: META MSTR MU MSFT INTC GOOGL DELL SOFI NFLX RIVN MRVL
• Dollar Tree upgraded on earnings upside potential despite ongoing traffic woes